|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
8
|
|
pubmed:dateCreated |
2009-12-16
|
|
pubmed:abstractText |
This phase 2 trial was designed to evaluate the efficacy and toxicity of a combination of docetaxel, gemcitabine, and oxaliplatin for platinum- and paclitaxel-pretreated epithelial ovarian cancer.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Nov
|
|
pubmed:issn |
1525-1438
|
|
pubmed:author |
|
|
pubmed:issnType |
Electronic
|
|
pubmed:volume |
19
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
1446-53
|
|
pubmed:meshHeading |
pubmed-meshheading:20009905-Adolescent,
pubmed-meshheading:20009905-Adult,
pubmed-meshheading:20009905-Aged,
pubmed-meshheading:20009905-Antineoplastic Combined Chemotherapy Protocols,
pubmed-meshheading:20009905-Deoxycytidine,
pubmed-meshheading:20009905-Fallopian Tube Neoplasms,
pubmed-meshheading:20009905-Female,
pubmed-meshheading:20009905-Humans,
pubmed-meshheading:20009905-Middle Aged,
pubmed-meshheading:20009905-Neoplasm Invasiveness,
pubmed-meshheading:20009905-Neoplasm Staging,
pubmed-meshheading:20009905-Organoplatinum Compounds,
pubmed-meshheading:20009905-Ovarian Neoplasms,
pubmed-meshheading:20009905-Paclitaxel,
pubmed-meshheading:20009905-Peritoneal Neoplasms,
pubmed-meshheading:20009905-Prognosis,
pubmed-meshheading:20009905-Prospective Studies,
pubmed-meshheading:20009905-Risk Factors,
pubmed-meshheading:20009905-Taxoids,
pubmed-meshheading:20009905-Treatment Outcome,
pubmed-meshheading:20009905-Young Adult
|
|
pubmed:year |
2009
|
|
pubmed:articleTitle |
Phase 2 trial of docetaxel, gemcitabine, and oxaliplatin combination chemotherapy in platinum- and paclitaxel-pretreated epithelial ovarian cancer.
|
|
pubmed:affiliation |
Department of Gynecology, Martin Luther University Halle-Wittenberg, Halle, Germany. gregor.seliger@medizin.uni-halle.de
|
|
pubmed:publicationType |
Journal Article,
Multicenter Study,
Clinical Trial, Phase II
|
